The Scientist

» biotechnology and microbiology

Most Recent

image: Narrow-Spectrum Antibiotic Could Spare the Microbiome

Narrow-Spectrum Antibiotic Could Spare the Microbiome

By | May 9, 2016

A drug that singles out Staphylococcus aureus leaves gut-dwelling microbiota largely intact, a mouse study shows.

0 Comments

image: Most Gut Microbes Can Be Cultured

Most Gut Microbes Can Be Cultured

By | May 4, 2016

Contrary to the popular thought that many species are “unculturable,” the majority of bacteria known to populate the human gut can be grown in the lab, scientists show.

0 Comments

image: Earth: Home to 1 Trillion Microbial Species

Earth: Home to 1 Trillion Microbial Species

By | May 4, 2016

A new analysis of microbial data estimates that the world is home to 1 trillion species—of which only 0.001 percent have been discovered.

0 Comments

image: Becoming Acculturated

Becoming Acculturated

By | May 1, 2016

Techniques for deep dives into the microbial dark matter

0 Comments

image: Lu on Syn Bio

Lu on Syn Bio

By | May 1, 2016

MIT researcher and Scientist to Watch Timothy Lu talks about the value of cross-disciplinary approaches in bringing synthetic biology into the clinic.

0 Comments

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: Microbial Ice-Makers

Microbial Ice-Makers

By | April 26, 2016

How one bacterium turns water into ice at nonfreezing temperatures

4 Comments

image: First Data from Anti-Aging Gene Therapy

First Data from Anti-Aging Gene Therapy

By | April 25, 2016

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

8 Comments

image: Theranos in Criminal Probe

Theranos in Criminal Probe

By | April 19, 2016

Federal officials are investigating whether the diagnostics company misled investors.

2 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS